TriSalus Life Sciences (TLSIW) Operating Leases (2022 - 2026)

TriSalus Life Sciences has reported Operating Leases for 5 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 8.39% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 8.39% YoY), and the FY2025 full-year result was $1.2 million, down 7.6% from the prior year.
• Operating Leases for Q1 2026 stood at $1.2 million, down from $1.2 million in the prior quarter.
• The five-year high for Operating Leases was $1.6 million in Q4 2022, with the low at $1.2 million in Q2 2024.
• Historically, Operating Leases has averaged $1.3 million across 5 years, with a median of $1.3 million in 2023.
• Annual changes were most pronounced in 2023 — Operating Leases dropped 21.91% — and 2024, when it increased 14.26%.
• TriSalus Life Sciences' Operating Leases stood at $1.6 million in 2022, then declined by 21.91% to $1.2 million in 2023, then rose by 6.83% to $1.3 million in 2024, then dropped by 7.6% to $1.2 million in 2025, then slipped by 3.09% to $1.2 million in 2026.
• The last three Operating Leases figures came in at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.